Evaluation of canine 2D cell cultures as models of myxomatous mitral valve degeneration.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
25
04
2019
accepted:
30
07
2019
entrez:
16
8
2019
pubmed:
16
8
2019
medline:
4
3
2020
Statut:
epublish
Résumé
The utility of cells cultured from the mitral valve as models of myxomatous diseases needs to be properly validated. In this study valve interstitial cells (VICs) and valve endothelial cells (VECs) were cultured from normal and diseased canine mitral valves in 2% (v/v) or 10% FBS media, in the presence of TGFβ1, 2 and 3, the TGFβ RI kinase inhibitor SB431542 and TGFβ neutralising antibodies, 5HT and the 5HT2RB antagonist LY272015. Cultures were examined by morphology, transcriptomic profiling, protein expression of the cell specific markers αSMA and SM22α (VICs), and CD31 (VECs), deposition of proteoglycans (PG), the PG versican, and the TGFβs themselves. VECs derived from normal valves were CD31+/αSMA-, but those from diseased valves were αSMA+, indicating endothelial-to-mesenchymal (EndoMT) transition had occurred. The TGFβs induced EndoMT in normal VECs, and this was abolished by SB431542, with significant changes in αSMA, CD31 and HAS2 expression (P<0.05). Normal VICs cultured in 10% FBS media were αSMA+ (activated myofibroblast (disease) phenotype), but were αSMA- when grown in 2% FBS. VICs from diseased dogs were αSMA+ in 2% FBS (retention of the activated myofibroblast disease phenotype), with significantly increased TGFβ1 expression (P<0.05) compared to normal cells. Treatment of normal and diseased VICs with the TGFβs significantly increased expression of αSMA, SM22α, versican, the TGFβs themselves, and deposition of PGs (P<0.05), with TGFβ1 being the most potent activator. These effects were either abolished or markedly reduced by SB431542 and a pan-TGFβ neutralizing antibody (P<0.05). SB431542 also markedly reduced αSMA expression in VICs from diseased valves, but 5HT and LY272015 had no effect on VIC phenotype. Transcriptomic profiling identified clear differences in gene expression for the different conditions and treatments that partially matched that seen in native diseased valve tissue, including changes in expression of ACTA2 (αSMA), 5HTR2B, TAGLN (SM22α) and MYH10 (SMemb), gene ontology terms and canonical signalling pathways. Normal and diseased VICs and normal VECs from canine mitral valves can be successfully grown in culture with retention of phenotype, which can be manipulated using TGFβ1 and the TGFβ RI kinase inhibitor SB431542. This optimized cell system can now be used to model MMVD to elucidate disease mechanisms and identify key regulators of disease progression.
Identifiants
pubmed: 31415646
doi: 10.1371/journal.pone.0221126
pii: PONE-D-19-11796
pmc: PMC6695117
doi:
Substances chimiques
Antigens, Differentiation
0
Types de publication
Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0221126Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Circulation. 2001 Nov 20;104(21):2525-32
pubmed: 11714645
Mol Pharmacol. 2002 Jul;62(1):58-64
pubmed: 12065755
Mol Pharmacol. 2002 Jul;62(1):65-74
pubmed: 12065756
Adv Vet Sci Comp Med. 1977;21:75-106
pubmed: 146409
Circ Res. 2004 Aug 6;95(3):253-60
pubmed: 15217906
J Heart Valve Dis. 2004 Sep;13(5):841-7
pubmed: 15473488
J Clin Invest. 2004 Dec;114(11):1586-92
pubmed: 15546004
Nat Genet. 2005 Mar;37(3):275-81
pubmed: 15731757
Matrix Biol. 2005 Sep;24(6):428-37
pubmed: 16055320
Immunology. 2006 May;118(1):10-24
pubmed: 16630019
Am J Vet Res. 2006 Aug;67(8):1307-18
pubmed: 16881841
Synapse. 2007 Jul;61(7):531-9
pubmed: 17447257
Histol Histopathol. 2007 Aug;22(8):873-82
pubmed: 17503344
Am J Pathol. 2007 Nov;171(5):1407-18
pubmed: 17823281
Am J Vet Res. 2008 Jun;69(6):763-9
pubmed: 18518656
Cardiovasc Pathol. 2009 Jul-Aug;18(4):191-7
pubmed: 18621549
J Comp Pathol. 2008 Aug-Oct;139(2-3):97-107
pubmed: 18640684
J Heart Valve Dis. 2008 Jul;17(4):402-11; discussion 412
pubmed: 18751470
J Heart Valve Dis. 2009 Jan;18(1):44-51
pubmed: 19301552
J Comp Pathol. 2009 Jul;141(1):41-51
pubmed: 19342061
J Vet Cardiol. 2009 Jun;11(1):1-7
pubmed: 19451044
Circulation. 2009 Jul 28;120(4):334-42
pubmed: 19597052
Am J Pathol. 2009 Sep;175(3):988-97
pubmed: 19679875
J Heart Valve Dis. 2010 Jan;19(1):71-8
pubmed: 20329492
Annu Rev Physiol. 2011;73:29-46
pubmed: 20809794
Proteomics Clin Appl. 2009 Dec;3(12):1422-9
pubmed: 21136961
Am J Vet Res. 2011 Feb;72(2):194-202
pubmed: 21281193
J Cardiovasc Transl Res. 2011 Dec;4(6):702-9
pubmed: 21892743
Res Vet Sci. 2012 Oct;93(2):879-85
pubmed: 22100243
J Cell Physiol. 2012 Jun;227(6):2595-604
pubmed: 22105615
Cardiovasc Res. 2012 Mar 1;93(3):480-9
pubmed: 22180604
J Vet Cardiol. 2012 Mar;14(1):7-17
pubmed: 22364692
J Vet Cardiol. 2012 Mar;14(1):223-30
pubmed: 22364693
J Vet Cardiol. 2012 Mar;14(1):59-71
pubmed: 22364722
J Vet Cardiol. 2012 Mar;14(1):211-21
pubmed: 22386586
Circulation. 2012 Apr 10;125(14):1795-808
pubmed: 22492947
Circulation. 2012 Sep 11;126(11 Suppl 1):S189-97
pubmed: 22965982
Cardiovasc Pathol. 2013 Jul-Aug;22(4):245-50
pubmed: 23261354
Vet J. 2013 Aug;197(2):388-94
pubmed: 23465752
Cardiovasc Res. 2013 Jul 1;99(1):175-84
pubmed: 23554457
J Vet Cardiol. 2013 Sep;15(3):171-80
pubmed: 23816827
Res Vet Sci. 2014 Dec;97(3):560-7
pubmed: 25458505
Vet J. 2015 Feb;203(2):192-8
pubmed: 25599900
J Mol Cell Cardiol. 2015 Mar;80:175-85
pubmed: 25633835
Vet J. 2015 Apr;204(1):32-9
pubmed: 25747697
Circ Cardiovasc Genet. 2015 Jun;8(3):516-28
pubmed: 25814644
Vet J. 2015 Apr;204(1):23-31
pubmed: 25841900
PLoS One. 2015 Jun 04;10(6):e0127844
pubmed: 26042674
Cardiovasc Pathol. 2015 Nov-Dec;24(6):359-67
pubmed: 26345253
Nat Rev Cardiol. 2015 Dec;12(12):689-710
pubmed: 26483167
Vet J. 2015 Dec;206(3):377-84
pubmed: 26586213
Vet J. 2016 May;211:45-51
pubmed: 27033593
J Comp Pathol. 2017 May;156(4):371-383
pubmed: 28408040
J Am Heart Assoc. 2017 Sep 14;6(9):
pubmed: 28912209
Vet Sci. 2017 Jul 17;4(3):null
pubmed: 29056693
J Mol Cell Cardiol. 2018 Feb;115:94-103
pubmed: 29291394
J Comp Pathol. 2018 Apr;160:23-33
pubmed: 29729718
J Small Anim Pract. 1974 Aug;15(8):511-22
pubmed: 4469562